Coverage at a glance
| Indication | Coverage |
|---|---|
| Type 2 diabetes | Covered with prior authorization |
Plan type: Commercial non-Medicare. Each indication below lists the BMI and clinical thresholds, the prior-authorization documentation, and the published policy it comes from.
Coverage by indication
What the prior authorization needs:
- Prior authorization required
- Patient is 18 years of age or older
- Diagnosis of type 2 diabetes (FDA-approved indication)
- Approval granted for 1 year
- Not combined with another GLP-1 agonist or GLP-1/GIP agonist
Policy CNF 360. Source: Diabetes: Glucagon-Like Peptide-1 Agonists Prior Authorization Policy (CNF 360). payer_policy. Verified August 27, 2026.
Recent change: On January 30, 2026, the FDA approved a name change moving Rybelsus 1.5 mg, 4 mg, and 9 mg tablets to Ozempic tablets. Rybelsus 3 mg, 7 mg, and 14 mg tablets remain on the market and stay covered under this policy for type 2 diabetes.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.
- Browse the prior-authorization letter library for a template that matches your plan and indication.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- If the prior-authorization request is denied, the appeal letter library has templates by denial reason, covering peer-to-peer review, Level 1 and Level 2 internal appeal, and external review.
- If your plan does not cover the indication you need, compare cash prices in the cost guide or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time. Some participants get a placebo, decided at random.
What it costs without insurance
The programs below bill you directly. Prices checked every Monday.
Frequently asked questions
Does Cigna cover Rybelsus?
Cigna, through its Express Scripts pharmacy benefit, covers Rybelsus for type 2 diabetes with prior authorization. The current policy approves it for one year when the patient is 18 years of age or older and has type 2 diabetes, with no step therapy and no A1C threshold in the standard criteria. Rybelsus is not covered for weight loss, because it is FDA-approved only for type 2 diabetes. The weight-loss semaglutide is Wegovy, which is given by injection and reviewed under a separate policy. This reflects the published policy verified August 2026.
What does Cigna require to approve Rybelsus?
For type 2 diabetes: Prior authorization is required, with the documentation listed in the requirements above.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
